CGuard Prime (carotid artery stent)

2024: Product Announcement

In early October 2024, the company InspireMD received permission to study stentings the carotid artery system CGuard Prime 80 cm to prevent embolization of the brain brain and development. stroke

With atherosclerosis of large vessels, blood clots may form on unstable plaques. These blood clots can break off under the pressure of blood flow, turning into thromboembols, which pass into vessels of increasingly smaller diameter until they block them. The most unfavorable complication in such cases is cerebral artery blockade with the development of stroke. The installation of a stent with a mesh in the aorta to delay thromboemboles prevents the development of these complications.

𝓲

InspireMD

As part of the pivotal CGUARDIANS II study, the new system will be used during transcarotide revascularization procedures to treat carotid artery stenosis. InspireMD CEO Marvin Slosman said in a news release that the new study will help prove that the system can be used in new indications, and will also be the basis for an optimized version of transcarotide revascularization.

The CGuard Embolism Prevention Stent System, designed to prevent stroke, was labeled CE in early 2024. The stent uses the company's patented MicroNet technology, which provides long-term safety in patients with atherosclerosis of large arteries. In parallel, the company continues to develop the next generation neuroprotection system.

All these initiatives will help us effectively start selling and take a leading place in the US market, says Slosman. - We aim to improve the possibilities of stroke prevention and control over carotid artery diseases and intend to capture both the domestic and international markets.[1]

Notes